Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Andrea Lora Kossler, MD, FACS

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Lina Badimón, MD, PhD

Faculty: Michelle O’Donoghue, MD, MPH

Faculty: Erin Michos, MD, MHS

Faculty: Pam R. Taub, MD

A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care. The course highlights women-specific cardiovascular risk modifiers, including reproductive and hormonal factors that are often under-recognized in risk assessment. It also emphasizes practical, multidisciplinary approaches to improving lipid management outcomes across diverse health systems.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment intensification, including androgen deprivation therapy–based combination approaches and the earlier use of androgen receptor pathway inhibitors in patients with high-risk disease. They also explore how advances in imaging, multidisciplinary care, and emerging clinical evidence are shaping treatment selection and timing. In addition, the discussion addresses practical considerations for managing adverse events associated with intensified therapy and incorporating these strategies into clinical practice.

Faculty: Neeraj Agarwal, MD, FASCO

Faculty: Rana McKay, MD

This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined.

Faculty: Muthiah Vaduganathan, MD, MPH

Faculty: Koichiro Kinugawa, MD

Faculty: Michael Böhm, MD

In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice.

Faculty: Alireza Atri, MD, PhD

Faculty: Raymond Scott Turner, MD, PhD

Faculty: Dani Cabral, MD

In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, practical implications for patients and care partners, and the potential impact on infusion-center burden and treatment access. Dr. Dani Cabral then speaks with a patient living with Alzheimer’s disease, who shares his perspective on using the subcutaneous formulation in the broader context of disease-modifying treatment and long-term management.

Faculty: Sayna Norouzi, MD

In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted therapies. Through a clinical patient vignette, Dr. Norouzi demonstrates patient-centered communication techniques for discussing mechanisms, treatment considerations, and long-term kidney preservation goals in clear, accessible language. Dr. Norouzi reviews key differences among treatment approaches, including mechanism of action, proteinuria reduction, kidney function stabilization, monitoring requirements, route of administration, adherence considerations, and infection risk. The activity also highlights the importance of vaccination review, ongoing monitoring, and aligning treatment decisions with patient priorities and lifestyle factors to support collaborative care planning and patient engagement in C3GN management.